Mentype® DIPquant assay now CE-IVD registered
February 7,

2019

Mentype® DIPquant assay now CE-IVD registered

Biotype Diagnostic expands highly specific CE-IVD portfolio for chimerism monitoring

Dresden-Hellerau, 07 February 2019. Biotype Diagnostic GmbH, in response to customer demand, now offers the qPCR kit Mentype® DIPquant as an in-vitro diagnostic with European approval. It is the third CE-IVD approved assay for chimerism analysis, alongside Mentype® Chimera® and Mentype® DIPscreen, and it extends the chimerism portfolio for use in in-vitro diagnostics.

Customers can now choose between five different products and three different technologies for chimerism monitoring. The analysis of the combination Mentype® DIPscreen and Mentype® DIPquant is based on the detection and quantification of DNA polymorphisms, caused by sequence deletion or insertion (DIP). Its achieved sensitivity is 0.05 %, which means that 5 out of 10,000 cells can already be detected.

Other existing products such as Mentype® Chimera®, Mentype® DigitalScreen, and Mentype® DigitalQuant are still available. Mentype® Chimera® allows chimerism monitoring by detecting characteristic Short Tandem Repeat (STR) sequences. Mentype® DigitalScreen and Mentype® DigitalQuant, on the other hand, use Droplet Digital PCR technology for absolute quantification. These two products are available as research use only (RUO) variants.

Further information can be found here.

Share This :